Nuzenio

Reaffirms Cash Runway

Reaffirms Cash Runway news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 10 latest news signals 4 publisher sources 100/100 entity strength

Latest news

Charged: Lucid reports earnings, reaffirms liquidity runway - TipRanksTipRanks · Mon, 10 Aug 2026 17:49:02 GMTOcugen: Buy Rating Reaffirmed as Cash Runway Extends to 2028 and Ophthalmology Pipeline Advances; $11 Price Target Maintained - TipRanksTipRanks · Sat, 08 Aug 2026 08:23:17 GMTCorbus Buy Rating Reaffirmed as Advancing Pipeline and Upcoming Catalysts Support Upside with Unchanged $38 Price Target - TipRanksTipRanks · Fri, 07 Aug 2026 20:28:21 GMTGenerate Biomedicines Reaffirmed at Buy as GB-0895 Progress and Cash Runway Support Unchanged $25 Price Target - TipRanksTipRanks · Fri, 07 Aug 2026 11:30:17 GMTPraxis Precision Medicines Reaffirmed With Buy Rating on FDA Progress and $1.4 Billion Cash Runway Supporting 2028 Launch Plans - TipRanksTipRanks · Fri, 07 Aug 2026 08:24:15 GMTAclaris Therapeutics reports Q2 2026 net loss of $21.5M, cash runway through 2028 - TradingViewTradingView · Thu, 06 Aug 2026 11:23:02 GMTIntellia Therapeutics Reports Positive Phase 3 HAELO Data for Lonvo-z, Advances Nex-z Trials and Reaffirms Cash Runway Into 2028 - Quiver QuantitativeQuiver Quantitative · Thu, 06 Aug 2026 11:15:00 GMTREGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights - TradingViewTradingView · Thu, 06 Aug 2026 11:05:00 GMT

Timeline

Mon, 10 Aug 2026 17:49:02 GMTCharged: Lucid reports earnings, reaffirms liquidity runway - TipRanks
Sat, 08 Aug 2026 08:23:17 GMTOcugen: Buy Rating Reaffirmed as Cash Runway Extends to 2028 and Ophthalmology Pipeline Advances; $11 Price Target Maintained - TipRanks
Fri, 07 Aug 2026 20:28:21 GMTCorbus Buy Rating Reaffirmed as Advancing Pipeline and Upcoming Catalysts Support Upside with Unchanged $38 Price Target - TipRanks
Fri, 07 Aug 2026 11:30:17 GMTGenerate Biomedicines Reaffirmed at Buy as GB-0895 Progress and Cash Runway Support Unchanged $25 Price Target - TipRanks
Fri, 07 Aug 2026 08:24:15 GMTPraxis Precision Medicines Reaffirmed With Buy Rating on FDA Progress and $1.4 Billion Cash Runway Supporting 2028 Launch Plans - TipRanks
Thu, 06 Aug 2026 11:23:02 GMTAclaris Therapeutics reports Q2 2026 net loss of $21.5M, cash runway through 2028 - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Reaffirms Cash Runway.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

4 distinct publisher/source names are currently connected to this entity page.